United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - ibandronic sodium monohydrate - solution for injection - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - ibandronic sodium monohydrate - solution for injection - 1mg/1ml

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - drugs for treatment of bone diseases - ibandronic acid 50mgibandronic acid teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - ibandronic acid - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - drugs for treatment of bone diseases - ibandronic acid is indicated in adults forprevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.treatment of tumour induced hypercalcaemia with or without metastases.treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - ibandronic sodium monohydrate - solution for injection - 1mg/1ml

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid (as monosodium monohydrate 3.375mg) - injection, solution - 3mg/3ml - ibandronic acid (as monosodium monohydrate 3.375mg) 3mg/3ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - ibandronic sodium monohydrate - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - ibandronic sodium monohydrate - solution for infusion - 1mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ibandronate sodium, quantity: 1.125 mg/ml (equivalent: ibandronic acid, qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - indicated for the treatment of: tumor-induced hypercalcaemia with or without metastases. metastatic bone disease in patients with breast cancer.